We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Integer Holdings
ITGR
$4.26B
| – | – |
-128
| Closed | -$10K |
|
627
Jabil
JBL
$35.8B
| – | – |
-842
| Closed | -$22K |
|
628
KLA
KLAC
$259B
| – | – |
-212,420
| Closed | -$2.54M |
|
629
Kinder Morgan
KMI
$68.7B
| – | – |
-20,045
| Closed | -$401K |
|
630
Knowles
KN
$3.34B
| – | – |
-48
| Closed | -$1K |
|
631
KRONOS Worldwide
KRO
$989M
| – | – |
-1,712
| Closed | -$24K |
|
632
Kohl's
KSS
$2.19B
| – | – |
-76,121
| Closed | -$5.24M |
|
|
LADR
633
Ladder Capital
LADR
$1.24B
| – | – |
-1,503
| Closed | -$26K |
|
634
Liberty Broadband Class A
LBRDA
$5.16B
| – | – |
-87,159
| Closed | -$7.99M |
|
635
LivaNova
LIVN
$4.2B
| – | – |
-80,741
| Closed | -$7.85M |
|
636
Live Oak Bancshares
LOB
$1.97B
| – | – |
-575
| Closed | -$8K |
|
637
Lowe's Companies
LOW
$125B
| – | – |
-19,692
| Closed | -$2.16M |
|
638
Louisiana-Pacific
LPX
$5.49B
| – | – |
-735
| Closed | -$18K |
|
639
Lam Research
LRCX
$390B
| – | – |
-1,470
| Closed | -$26K |
|
640
Stride
LRN
$3.43B
| – | – |
-628
| Closed | -$21K |
|
641
Lumen
LUMN
$6.44B
| – | – |
-1,045
| Closed | -$13K |
|
642
Moelis & Co
MC
$4.94B
| – | – |
-602
| Closed | -$25K |
|
643
Medpace
MEDP
$16.5B
| – | – |
-481
| Closed | -$28K |
|
644
MGP Ingredients
MGPI
$375M
| – | – |
-283,809
| Closed | -$21.9M |
|
645
MKS Inc
MKSI
$20.6B
| – | – |
-217,076
| Closed | -$20.2M |
|
646
Maximus
MMS
$3.1B
| – | – |
-368
| Closed | -$26K |
|
647
Strategy Inc
MSTR
$38.4B
| – | – |
-720
| Closed | -$10K |
|
648
MGIC Investment
MTG
$6.25B
| – | – |
-1,953
| Closed | -$26K |
|
649
Micron Technology
MU
$991B
| – | – |
-558
| Closed | -$23K |
|
650
Myriad Genetics
MYGN
$312M
| – | – |
-475,806
| Closed | -$15.8M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.